As of June 21, 2025, Gene Biotherapeutics Inc (CRXM) reports a Net Margin of -8163.27%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Gene Biotherapeutics Inc's Net Margin
Over recent years, Gene Biotherapeutics Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2020-12-31 | -8163.27% |
| 2019-12-31 | -8163.27% |
| 2018-12-31 | -14009.95% |
This fluctuation highlights how Gene Biotherapeutics Inc manages its overall profitability and cost control over time.
Comparing Gene Biotherapeutics Inc's Net Margin to Peers
To better understand Gene Biotherapeutics Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Gene Biotherapeutics Inc (CRXM) | -8163.27% |
| Forward Pharma A/S (FWP) | 73.37% |
| Protalix Biotherapeutics Inc (PLX) | 5.49% |
| Globeimmune Inc (GBIM) | -42.85% |
| Lattice Biologics Ltd (LBL.V) | -60.16% |
| Sangui Biotech International Inc (SGBI) | -85.72% |
Compared to its competitors, Gene Biotherapeutics Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.